Recombinant Human NKp30-Fc Chimera (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
CD337, NCR3, LY117, IC7, CD337 Antigen
Ave. Rating
Submit a Review
Product Citations
publications
Recom_Human-NKp30_1_CF
Immobilized recombinant human NKp30-Fc chimera binds to biotinylated recombinant human B7-H6-Fc chimera in a dose-dependent manner. The ED50 for this effect is 4 – 20 ng/mL.
  • Recom_Human-NKp30_1_CF
    Immobilized recombinant human NKp30-Fc chimera binds to biotinylated recombinant human B7-H6-Fc chimera in a dose-dependent manner. The ED50 for this effect is 4 – 20 ng/mL.
  • Recom_Human-NKp30_2_CF
    Stability Testing for Recombinant Human NKp30-Fc Chimera. Recombinant human NKp30-Fc chimera was aliquoted in PBS, pH 7.2 at 0.2 mg/mL and one aliquot was kept at 4°C (Control), and another was frozen and thawed four times (4x Freeze/Thaw). The samples were tested by their property to bind to biotinylated recombinant human B7-H6 in a dose-dependent manner. The ED50 for this effect is 4 – 20 ng/mL.
Cat # Size Price Quantity Check Availability Save
579204 25 µg 380 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
579206 100 µg 790 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NKp30 is Type I transmembrane (TM) natural cytotoxic receptor (NCR) with a single Ig-like extracellular domain. NKp30 has a molecular weight of 30 kD with six isoforms formed by alternative splicing. Three NCRs has been described NKp46, NKp44, and NKp30 encoded by NCR1, NCR2, and NCR3 respectively.  NCRs are activating receptors for anti-viral and anti-tumor activity of NK cells. NKp30 is expressed on resting and activated NK cells and enhances NK cell cytolysis of tumor cells that are deficient in MHC class I molecules. Interaction of NKp30 with BAG6 promotes myeloid DC maturation by activating and expanding resting NK cells. In addition, NKp30 and BAG6 interaction induces release of TNFα and IFNγ from NK cells and therefore affects DC maturation. Decreased expression of NKp30 in peripheral NK cells is related to gastric cancer progression.

Product Details
Technical Data Sheet (pdf)

Product Details

Source
Human NKp30, amino acid sequence (Leu19-Thr138) (Accession: #O14931.1), was expressed in 293E cells. The carboxy-terminus contains IEGRMD linker and human IgG (Pro100-Lys330).
Molecular Mass
The 357 amino acid recombinant protein has a predicted molecular mass of approximately 39.7 kD. The DTT-reduced and non-reduced proteins migrate at approximately 50 - 60 kD and 90 – 100 kD by SDS-PAGE. The predicted N-terminal amino acid is Ala.
Purity
> 95%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.22 µm filtered protein solution is in PBS, pH 7.2
Endotoxin Level
Less than 0.1 EU per µg of cytokine as determined by the LAL method.
Concentration
25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin the vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
Immobilized recombinant human NKp30 binds biotinylated recombinant human B7-H6 in a dose-dependent manner. The ED50 for this effect is 4 – 20 ng/mL.
Application

Bioassay

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Antigen Details

Structure
Monomer
Distribution

Mature and resting NK cells, plasmacytoid dendritic cells, small intestine TCRαβ+ CD8+ IEL

Function
Induction of NK-mediated cytotoxicity, lysis of virus-infected cells and transformed cells
Interaction
Cancer cells, pathogen infected cells
Ligand/Receptor
B7-H6, Hemagglutinin protein from Vaccinia virus, pp65 matrix protein of human cytomegalovirus (HCMV), Nuclear factor BAT3
Bioactivity
Immobilized recombinant NKp30 binds biotinylated recombinant B7-H6.
Cell Type
NK cells, T cells
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Pende D, et al. 1999. J Exp Med. 190:1505-16.
  2. Bloushtain N, et al. 2004. J Immunol. 173:2392-401.
  3. Arnon TI, et al. 2005. Nat Immunol. 6:515-23.
  4. Byrd A, et al. 2007. PLoS ONE. 2:e1339.
  5. Brandt CS, et al. 2009. J Exp Med. 206:1495-503.
  6. Jarahian M, et al. 2011. PLoS Pathog. 7:e1002195.
  7. Han B, et al. 2018. J Immunol Res. 2018:6248590.
  8. Barrow AD, et al. 2019. Front Immunol. 10:909.
Gene ID
259197 View all products for this Gene ID
UniProt
View information about NKp30 on UniProt.org

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Go To Top Version: 1    Revision Date: 06.27.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account